Maslimomab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Mouse |
| Target | T-cell receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Maslimomab is a mouse monoclonal antibody[1] and an immunosuppressive drug.[2] It is an anti-human T-cell receptor alpha/beta chain.[1]
References
[edit]- ^ a b "Proposed International Nonproprietary Names: Maslimomab" (PDF). WHO Drug Information. 5 (4). Geneva: World Health Organization: 201. 1991. Archived from the original (PDF) on 23 February 2012.
- ^ Pelletier JP, Mukhtar F (January 2020). "Passive monoclonal and polyclonal antibody therapies.". Immunologic Concepts in Transfusion Medicine. Philadelphia: Elsevier. pp. 251–348 (299). doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9. PMC 7153350.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |